#2730 MESENCHYMAL STEM CELLS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS

Abstract Background and Aims Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease of unknown aetiology affecting various organs tissues. In the last decade, alternative therapeutic methods for SLE refractory to immunosuppressive therapy have been actively studied. Of interest are data transplantation mesenchymal stem cells (MSCs) that demonstrated immunomodulatory properties, as well ability self-renewal multi-lineage differentiation. Objective evaluate efficacy safety MSCs in patients with severe SLE. Method The search was conducted on PubMed Google Scholar platforms using following strategy: “Systematic erythematosus” plus “Mesenchymal cells”. All articles presented these domains published before 01.12.2022 format case reports, clinical studies, trials, multicentre studies were analysed. effectiveness evaluated systemic activity index SELENA-SLEDAI, renal functional parameters (daily proteinuria, creatinine, glomerular filtration rate (GFR), serum albumin), immunological (anti-nuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA). assessment included registration adverse events during after transplantation. Results A total 201 publications retrieved period from 2000-2022, 24 records about treatment met above criteria study. analysed obtained biological sources such bone marrow, adipose tissue, umbilical cord. total, results transplantations 806 average age 30.5±8.53 years old (from 12 62 years). suggested there significant decrease SLE: 2.5-fold reduce SELENA-SLEDAI score months 12.43±3.06 5.02±2.12). Anti-dsDNA titer dropped 399.05±477.86 227.65±130.76. Some research also revealed ANA 309.64±412.75 187.8±146.60. improvement kidney function assessed by 2.17-fold reduction daily proteinuria 2.48±0.66 1.14±0.56 g/l an increase GFR 66.84±42.2 83.25±44.90 ml/min. Furthermore, majority cases who had treated conventional immunosuppressants glucocorticoids no response, dosage reduced. essential application. all (n = 806) underwent few side effects nausea 7), herpes 2), agranulocytosis fungal pneumonia tuberculosis 3). No tumor-related observed. Mortality consists 2.6%, multiple organ failure 19), others - acute heart 1) 1). Thus, survival 97.4%. Conclusion According analysis currently available effect injury: indicators. follow-up serious events, or patients.